MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) has issued equity awards to newly hired staff, a move that reflects continued investment in talent as the medical technology company advances its commercial strategy.
The company said the Compensation Committee of its Board of Directors approved inducement grants of restricted stock units covering a total of 3,600 shares of common stock for three new employees. The grants were awarded on December 9, 2025, and were tied directly to the individuals’ acceptance of employment with the company.
The awards were made under the Nasdaq Rule 5635(c)(4) inducement grant exception, which allows companies to issue equity compensation outside shareholder-approved plans when such awards are a material incentive for new hires. TELA Bio said the grants form part of each employee’s overall compensation package.
Under the terms of the awards, the restricted stock units vest in equal annual installments over a four-year period, contingent on the employees’ continued service with the company through each vesting date.
TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions designed to preserve and restore a patient’s own anatomy. Its products emphasize the use of biologically derived materials intended to support the body’s natural healing process while reducing reliance on permanent synthetic implants.
The company positions its technology as both clinically effective and economically efficient, targeting surgeons seeking alternatives that balance durability, patient outcomes, and long-term safety considerations.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.